At TLD Group, we’ve spent a lot of time over the past few months considering the massive changes that are taking place in the health ecosystem, as well as the leaders whose jobs are changing every day because of these disruptions. This month, we’re honing in on the state of life sciences and its impact on executives, specifically leaders in the pharmaceutical sector, who play a critical role in the health ecosystem through researching, developing, and distributing vital treatments.
The pandemic has shaken up the very nature of work, making a lasting impact on organizations and business leaders across all industries. The biggest impact, however, has been felt by organizations that comprise the health ecosystem as they stepped up and rallied to respond to the challenges their communities faced during the pandemic. Many key players in the health ecosystem have illustrated what is possible when leaders from different organizations and diverse industry sectors collaborate to meet critical challenges and align around a shared purpose.
Before the World Health Organization (WHO) declared COVID-19 a pandemic, pharmaceutical companies like Pfizer, Moderna, Johnson & Johnson and Gilead were often tagged as “big pharma” putting profit before purpose.
Now, one year later, pharmaceutical companies are being praised for their positive impact resulting from the speed at which they were capable of producing FDA-approved treatments and vaccines for COVID-19.
Through its ingenuity, strategic leadership and nimble pipeline management practices, the pharmaceutical industry is meeting a deep and drastic human need: to keep ourselves and our loved ones healthy and alive.